Testosterone News and Research

Latest Testosterone News and Research

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

8 Apr 2009

Male baby comes with more risks than females

Nurses in the maternity ward often say that a difficult labor is a sign of a baby boy.

1 Apr 2009

Testosterone doping tests in sport ignore ethnic differences in hormone activity

Current steroid (testosterone) doping tests should be scrapped for international sport, because they ignore vital ethnic differences in hormone activity, suggests research published ahead of print in the British Journal of Sports Medicine.

11 Mar 2009

Hormone imbalance from obesity impacts sex life

Hormonal changes and diminished sexual quality of life among obese men are related to the degree of obesity, and both are improved after gastric bypass surgery according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

3 Mar 2009

Marijuana use may increase risk of testicular cancer

Frequent and/or long-term marijuana use may significantly increase a man's risk of developing the most aggressive type of testicular cancer, according to a study by researchers at Fred Hutchinson Cancer Research Center.

9 Feb 2009

At last a male contraceptive jab!

At last a male contraceptive jab has been developed and is all set to be trialled - and Sydney men will be the first guinea pigs!

3 Feb 2009

Water pollution linked to male fertility problems

New research strengthens the link between water pollution and rising male fertility problems.

19 Jan 2009

Hormones make pretty women serial monogamists

American researchers say women with high levels of estrogen feel more attractive and are far more likely to indulge in affairs.

18 Jan 2009

New evidence suggests preventive effect of herbal supplement in prostate cancer

DHEA is a natural circulating hormone and the body's production of it decreases with age.

12 Jan 2009

Possible test for autism raises calls for an ethical debate

New research by British scientists means prenatal testing for autism is a possibility, but has evoked calls for an ethical debate on the issue.

12 Jan 2009

Endo Pharmaceuticals to acquire Indevus Pharmaceuticals

Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.

5 Jan 2009

Why prostate cancer patients fail hormone deprivation therapy

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years.

1 Jan 2009

FDA approves injectable drug degarelix for advanced prostate cancer

The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.

29 Dec 2008

EPA should assess health risk of phthalates and other chemicals

The U.S. Environmental Protection Agency should examine whether combined exposures to chemicals known as phthalates could cause adverse health effects in humans, says a new report from the National Research Council. In addition, this analysis, called a cumulative risk assessment, should consider other chemicals that could potentially cause the same health effects as phthalates, instead of focusing on chemicals that are similar in structure, which is EPA's current practice.

18 Dec 2008

AEterna Zentari completes recruitment for phase 3 trial with Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. has reported it has reached its goal of recruiting 500 patients for the safety study of the Phase 3 program in benign prostatic hyperplasia (BPH) with its flagship product candidate, cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist.

11 Dec 2008